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Washing cord blood (CB) grafts involves product manipulation and may result in cell loss. We investigated
double-unit CB transplantation (CBT) using red blood cell (RBC)edepleted units diluted with albumin-
dextran in patients with hematologic malignancies. One-hundred thirty-six patients (median age, 43
years; range, 4 to 71; median weight, 69 kilograms (kg); range, 24 to 111) underwent transplantation with a
4/6 to 6/6 HLA-matched graft. Patients  20 kg were excluded, as they only received washed units. Units
were diluted a median of 8 fold to a median volume of 200 mL/unit. The median infused total nucleated cell
doses were 2.7 (larger unit) and 2.0 (smaller unit) x 107/kg, respectively, and the median post-thaw recovery
was 86%. Units were infused consecutively (median, 45 minutes/unit). While only 17 patients (13%) had no
infusion reactions, reactions in the remaining 119 patients were almost exclusively mild-moderate (by
CTCAE v4 criteria 12 grade 1, 43 grade 2, 63 grade 3) with only 1 patient (< 1%) having a severe (grade 4)
reaction. Moreover, most were easily treated. Grade 2 to 3 hypertension was the most common in 101 (74%)
patients. The cumulative incidence of sustained donor-derived neutrophil engraftment was high: 95% in
myeloablative and 94% in nonmyeloablative CBT recipients. With appropriate supportive care, double-unit
CBT with RBC-depleted grafts infused after albumin-dextran dilution is safe with high rates of engraft-
ment in patients > 20 kg.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION infused as a bedside thaw. This has led the NMDP to
Cord blood (CB) is routinely used as an alternative he-
matopoietic stem cell source. Traditionally, CB is thawed
using albumin-dextran dilution followed by centrifugation
and resuspension, ie, “wash” [1]. However, the wash of CB
grafts involves additional product manipulation, risks po-
tential cell loss and potential contamination, requires
increased technologist time, and delays time to infusion [2].
A faster and easier alternative is albumin-dextran dilution
without centrifugation [3,4]. This approach is controversial,
however, as the infusion of nonwashed CB has been associ-
ated with severe or lethal infusion reactions at some centers
[5] [2009 United States National Marrow Donor Program
(NMDP) communication]. The majority of nonwashed units
associated with such serious infusion reactions, however,
have been RBC-replete, and the risk of severe infusion re-
actions appears to be greatly increased if the units areedgments on page 494.
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13.12.561recommend that bedside thaw of RBC-replete units be
avoided.
We have previously demonstrated in 54 double-unit CBT
recipients weighing > 20 kg that the use of albumin-dextran
dilution without centrifugation is feasible [3]. However, in
that report, 3 patients who received 1 of 2 units that were
RBC-replete and infused after dilution had signiﬁcant
(although nonlethal) infusion reactions. Therefore, since
2009, only RBC-depleted units are considered for the “no
wash” approach at Memorial Sloan-Kettering Cancer Center
(MSKCC). We now report the safety (infusion reactions) and
efﬁcacy (engraftment) of this approach in 136 patients who
underwent transplantation with RBC-depleted double-unit
CB grafts thawed with albumin-dextran dilutionwith a focus
on the nature, severity, and management of infusion
reactions.MATERIALS AND METHODS
Patients and CB Grafts
This is a retrospective analysis of 136 consecutive double-unit CBT re-
cipients who underwent transplantation between February 2006 and
November 2012 at MSKCC for the treatment of hematological malignanciesTransplantation.
Table 1
Patient Characteristics
Patient Characteristic Value
No. of patients 136
Age, median (range), yr 43 (4-71)
Weight, median (range), kg 69 (24-111)
Diagnosis
Acute leukemia 73 (54%)
MDS/myeloproliferative disease 9 (7%)
NHL/HD/CLL 54 (40%)
Disease risk
Standard 18 (13%)
High 118 (87%)
Conditioning intensity
High dose
Chemo þ TBI 1320-1375 cGy 38 (28%)
Clo100-150/Mel 140/Thio 10 7 (5%)
Reduced intensity
Flu 150/ Cy 50/ Thio 10/ TBI 400 cGy 48 (35%)
Mel 140/ Flu 150 8 (6%)
Flu/TBI/decitabine/6 Thioguanine 1 (1%)
Nonmyeloablative
Flu150/Cy50/TBI 200 cGy 34 (25%)
MDS indicates myelodysplasia; NHL, non-Hodgkin lymphoma; HD, Hodgkin
lymphoma; CLL, chronic lymphocytic leukemia; Chemo, chemotherapy; TBI,
total body irradiation; Clo, clofarabine; Mel, melphalan; Thio, thiotepa; Flu,
ﬂudarabine; Cy, cyclophosphamide.
Data presented are n (%) unless otherwise indicated.
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weight and received 2 RBC-depleted CB units as their ﬁrst allograft for the
treatment of acute leukemia in morphologic remission or aplasia, myelo-
dysplasia, or lymphoma. Double-unit grafts were used to augment
engraftment [6-8] and potentially protect against relapse [9-13]. Twenty
kilogramswas set as the lower limit of recipientweight for administration of
nonwashed CB, given the higher risk of dimethyl sulfoxide toxicity in smaller
patients [14]. Furthermore, small pediatric patients may not tolerate large
infusion volumes, and the potential cell loss with awash has little impact on
the infused total nucleated cell (TNC) dose in this group. During the time
period of the study, 20 patients received double-unit CBT but were excluded
from this analysis. In 14 small children, both units were washed. In 4 pa-
tients who underwent transplantation early in the study period, 1 of the
units of the graft was RBC replete but was not washed, and in the remaining
2 patients, 1 unit of the graft was washed because of being RBC replete.
The 136 recipients of grafts prepared with albumin-dextran dilution
received myeloablative or nonmyeloablative conditioning according to pa-
tient age, extent of prior therapy, comorbidities, and diagnosis. All patients
received a calcineurin-inhibitor and mycophenolate mofetil immunosup-
pression and post-transplantation granulocyte colony-stimulating factor.
Units were selected according to their TNC dose, human leukocyte antigen
(HLA)-A, -B antigen, -DRB1 allele match, and bank of origin [15]. All patients
or their guardians signed informed consent before transplantation. Fifty of
the 136 patients in this study have previously been reported in 2009 [3].
Preparation of CB Units for Infusion
Units were stored at  180C upon arrival at MSKCC. Each unit was
thawed separately as previously described [3]. In brief, units were thawed in
a 37C water bath and transferred to a bio-safety cabinet. A stock diluent
solution with a 5:1 ratio of 10% dextran 40 (molecular weight 40,000,
Hospira, Lake Forest, IL) and 25% human serum albumin (CSL Behring,
Kankakee, IL) was prepared at room temperature and aliquoted into 300 mL
or 600 mL transfer packs for units in single compartment bags or MedSep
double compartment units, respectively. All units were diluted 6 fold with
the standard dilution being 8 fold for a ﬁnal volume of at least 200 mL/unit.
Diluent approximately equal to the cryopreserved volume of the unit was
slowly transferred to the cryo-bag. Once a 1:1 dilution was achieved, the
tubing was clamped. After thorough mixing, the product was allowed to
equilibrate for 1 to 2minutes. It was then drained back into the transfer pack
or cell wash infusion bag to achieve the ﬁnal dilution. Units frozen in 2 bags
were combined after albumin reconstitution before samples were taken.
CB Unit Assessment
A small aliquot was removed from the albumin-dextranediluted units
for RBC count, TNC count, ABO blood group, culture, and assays of unit
quality. Unit quality was evaluated by ﬂow cytometric assay of CD34þ cell
viability using 7-amino-actinomycin D [16], and colony-forming unit assays.
Colony-forming unit assays were performed using a total of 1 x 105 cells
plated in duplicate and colony growth was evaluated by light microscopy at
14 days. The RBC volume (mL/kg) was calculated as follows: mean corpus-
cular volume (110 for CB) x post-thaw RBC content (per L) x ﬁnal product
volume (mL)/kg of patient weight.
Management of CB Infusion and Infusion Reactions
All patients received premedications, mostly with oral acetaminophen,
intravenous diphenhydramine (or hydroxyzine), and intravenous lorazepam.
In addition, patients received hydration approximately twice: maintenance
4 to 6 hours before transplantation and 12 to 24 hours after transplantation.
Experienced transplantation nurses or physicians were present during
infusion of both units and patients were closely monitored. Vital signs were
monitored before the start of the infusion of each unit, every 15 minutes
during infusion, at the completion of infusion, and then every 15minutes x 2,
every 30 minutes x 2, and every 60 minutes x 4, and subsequently every
4 hours. Each unit was administered to completion within 4 hours of thaw.
Emergency medications, including intravenous lorazepam, hydralazine,
furosemide, hydrocortisone, and oxygen were at the bedside for immediate
administration, if needed.
Deﬁnitions
Infusion reactions were graded according to the Common Terminology
Criteria for Adverse Events version 4 (CTCAE v4.0). A serious infusion reaction
was deﬁned as any life-threatening (grade 4) or lethal (grade 5) event related
to CB infusion, such as anaphylaxis, acute renal failure, seizure, transfer to
intensive care unit, or death within 48 hours of CB infusion. Grade 1 hyper-
tension was systolic blood pressure 120 to 139 mm Hg or diastolic 80 to
89mmHg, grade 2 was systolic 140 to 159mmHg or diastolic 9 to 99mmHg
or symptomatic increase by > 20 mm Hg, grade 3 was systolic  160 mm Hg
or diastolic  100 mm Hg, and grade 4 was life-threatening consequences(eg, neurologic deﬁcit or hypertensive crisis). Grade 1 nausea/vomiting was
nausea requiring intravenous medications or 1 to 2 episodes of vomiting
separated by 5 minutes in 24 hours. Bradycardia (heart rate < 60 beats/
minute) or tachycardia (> 100 beats/minute) had grade 1 severity if they
were asymptomatic and interventionwas not indicated, whereas grade 2was
symptomatic and medical intervention was required. Grade 2 hypoxia was
decreased oxygen saturation < 88% or intermittent supplemental oxygen. In
addition, for the purposes of this analysis, we deﬁned renal insufﬁciency as a
1.5-fold increase in serum creatinine over the day 0 baseline and greater than
the upper limit of normal for age.
As neonatal blood does not contain isohemagglutinins [17], only major
ABO incompatibilities between patients and CB units were considered for
possible association with infusion reactions. The following donor/recipient
pairings deﬁned major ABO incompatibility: AB CB unit infused into an A, B,
or O recipient; an A CB unit infused into a B or O recipient; and a B CB unit
infused into an A or O recipient.
Assessment of Donor Engraftment
Time to neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive
days with an absolute neutrophil count  .5 x 109/L. Time to platelet re-
covery was deﬁned as the ﬁrst of 3 consecutive days at  20 x 109/L and at
least 7 days without platelet transfusion support. Sustained engraftment
was deﬁned as sustained donor-derived neutrophil recovery with donor
chimerism of at least 90% (both units combined). The probabilities of
neutrophil and platelet engraftment were computed using the cumulative
incidence function with early death being the competing risk.
RESULTS
Patients and CB Grafts
Patient characteristics are summarized in Table 1. The 136
consecutive patients (median age, 43 years; median weight,
69 kg) underwent transplantation for high- or standard-risk
hematological malignancies. Eighteen patients were children
(ages 4 to 16 years). Conditioning was myeloablative (n ¼
102) or nonmyeloablative (n ¼ 34). The 272 units were ob-
tained from domestic (n¼ 198, 73%) or international (n¼ 74,
27%) banks. The units were 6/6 (n ¼ 14, 5%), 5/6 (n ¼ 134,
49%), and 4/6 (n ¼ 124, 46%) HLA matched to the patient.
CB units were diluted to a median of 8 fold (Table 2). All
patients received diluted grafts, except for 1 who developed
a CTCAE v4.0 grade IV anaphylaxis at initiation of infusion of
the ﬁrst unit. This patient’s infusion was aborted and the
graft was washed. The median infused TNC doses x 107/kg of
Table 2
Characteristics of CB Grafts after Albumin-Dextran Reconstitution*
Unit Characteristics Value
Median volume, (range), mL
Pre-thaw 25 (21-80)
Post-thaw 200 (200-600)
Fold dilution 8 (6-12)
TNC, median (range), x 107/kg
Prethaw (n ¼ 270) 2.7 (1.1-7.5)
Postthaw (n ¼ 270) 2.3 (.9-6.9)
TNC recovery, % (range) 86% (50-125)
Infused TNC, median (range), x 107/kg
Larger unit (n ¼ 135) 2.7 (1.4-6.9)
Smaller unit (n ¼ 135) 2.0 (.9-4.5)
Infused CD34þ, median (range), x 105/kg
Larger unit (n ¼ 135) 1.3 (.3-4.5)
Smaller unit (n ¼ 135) .7 (.1-2.1)
Infused CFU, median (range), x 104/kg
Larger unit (n ¼ 135) 3.7 (.4-18.4)
Smaller unit (n ¼ 135) 1.8 (.01-7.2)
CD34þ cell viabilityy, median (range) 93% (34%-99%)
TNC indicates total nucleated cell; kg, kilogram; CFU, colony-forming unit.
Includes 270 units in 135 grafts.
* One graft is excluded as it was washed in the patient with a grade
4 reaction.
y Reﬂects post-thaw measurement.
Table 3A
Infusion Reactions by Type and CTCAE v4 Grade
Grade HTN N  V Cardiopulmonary* Allergicy Otherz Total
1 8 22 11 - 3 44
2 38 - 8 - 2 48
3 63 - - 1 - 64
4 - - - 1 - 1
5 - - - - - -
Total 109 22 19 2 5 157
HTN indicates hypertension; CTCAE v4, Common Terminology Criteria for
Adverse Events version 4; N, nausea; V, vomiting.
Includes a total of 157 reactions in 119 patients.
* Cardiopulmonary reactions included bradycardia, tachycardia, chest
pain, dyspnea, wheezing, hypoxia, or cough.
y Allergic reactions are angioedema or anaphylaxis.
z Other reactions include fever, chills, shoulder, or abdominal pain.
Table 3B
Details of Infusion Reactions (Grade 1 to 4) Listed by Maximal Grade*
Infusion Reactions by Maximum Grade (CTCAE v4 criteria) n
Grade 1 (n ¼ 12 of total 136, 9%)
HTN 4
HTN, N  V 1
HTN, bradycardia, N  V 1
Bradycardia 1
Bradycardia, N  V, abdominal pain 1
N  V 3
Coughing, shoulder pain 1
Grade 2 (n ¼ 43 of total 136, 32%)
HTN 32
HTN þ grade 1 bradycardia 1
HTN þ grade 1 N  V 5
Wheezing 2
Hypoxia þ grade 1 N  V 2
Hypoxia þ grade 1 HTN 1
Grade 3 (n ¼ 63 of total 136, 46%)
HTN 46
HTN þ grade 1 N  V 6
HTN þ grade 1 N  V, chest tightness, dyspneay, tachycardia 1
HTN þ grade 1 N  V, chest pain 1
HTN þ grade 2 hypoxia 2
HTN þ grade 1 dyspneay 1
HTN þ grade 1 tachycardia 1
HTN þ grade 2 chills, grade 1 chest pain, 1
HTN þ grade 2 hypoxia, grade 1 bradycardia, chest pain 1
HTN þ grade 3 angioedema, grade 1 bradycardia, N  V 1
HTN þ grade 2 chills, grade 1 fever 1
HTN þ grade 1 chills 1
Grade 4 (n ¼ 1 of total 136, < 1%)
Anaphylaxis þ grade 1 HTN 1
CTCAE v4 indicates Common Terminology Criteria for Adverse Events
version 4; N, nausea; V, vomiting; HTN, hypertension; sat, saturation.
* Of 136 patients, 119 had grade 1 to 4 reactions, whereas 17 patients had
no reactions.
y Normal oxygen saturation.
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2.0 (smaller unit), respectively, with a median TNC recovery
of 86%.
Administration of Diluted CB Products
Each unit was administeredwithin approximately 60 to 90
minutes of dilution. Themedian time between premedication
and initiation of the ﬁrst unit was 48 minutes (range, 5 to 100
minutes). CB units were infused consecutively shortly after
thaw. The median interval between infusion of the ﬁrst and
second unit was 15 minutes (range, 3 to 133 minutes). The
median time to infuse each unit was 45 minutes (range, 15 to
285 minutes), and the median time to infuse the entire
diluted graft was 115 minutes (range, 42 to 438).
Infusion Reactions
The frequency, nature, and severity of infusion reactions
by CTCAE v4.0 criteria are shown in Tables 3A and 3B. There
were no grade 5 (lethal) infusion reactions. Although only 17
patients (13%) had no reactions, most reactions were mild to
moderate and easily treated. By CTCAE v4.0 criteria, 12 of a
total of 136 (9%) patients had grade 1 reactions, 43 (32%)
grade 2, 63 (46%) grade 3, and only 1 (< 1%) patient had a
grade 4 reaction.
The most common infusion reaction was hypertension.
Eight patients had grade 1, 38 had grade 2, and 63 had grade
3 hypertension (systolic 160 mmHg or diastolic  100 mm
Hg). Thirty patients did not require treatment because of
prompt spontaneous resolution of hypertension, whereas
79 patients (58% of patients overall) were treated with hy-
dralazine, furosemide, or both. For the patients with themost
severe hypertension (grade 3), the onset was during the ﬁrst
unit in 37 patients and during the second unit in 26. In this
grade 3 group, the median peak systolic blood pressure
overall was 161 mm Hg (range, 132 to 213) and the median
peak diastolic was 101 mm Hg (range, 83 to 140).
The second most common reaction was nausea and/ or
vomiting, which affected 22 (14%) patients; all were of grade 1
severity and were managed by antiemetics (usually loraze-
pam). The next most common reaction was cardiopulmonarysymptoms, which occurred in 19 patients. These included
bradycardia, tachycardia, dyspnea, wheezing, hypoxia, cough,
or chest pain/tightness. Six patients had bradycardia, ranging
from 42 to 56 beats per minute. All were asymptomatic and
resolved without intervention. Two patients had tachycardia
at 119 and 124 beats/minute; both resolved without inter-
vention. Six patients had transient hypoxia with a minimum
oxygen saturation ranging from 88% to 93%. All weremanaged
with oxygen by nasal cannulae and 3 patients received
nebulized bronchodilator. Overall, cardiopulmonary symp-
toms developed during the ﬁrst unit in 7 patients and with
the second unit in 12.
Severe reactions were rare. One patient had grade 3
angioedema along with grade 3 hypertension, grade 1
Figure 1. The cumulative incidence of sustained donor neutrophil engraftment (1A) and platelet engraftment (1B) after double-unit CBT performed with albumin-
dextran dilution according to conditioning regimen intensity. For nonmyeloablative recipients, although early count recovery may have been autologous, only those
with sustained donor-derived count recovery are counted as having engrafted.
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angioedema involved hoarse voice and facial and lip swelling
and it developed approximately 10 minutes into the ﬁrst unit.
Symptoms were managed with corticosteroids, diphenhy-
dramine, oxygen via nasal cannula, and slowing the infusion.
A second patient developed a grade 4 anaphylaxis-type re-
action with severe bronchospasm, hypoxia (oxygen satura-
tion, 89%) approximately 10mL into the ﬁrst unit, and grade 1
hypertension (132/82 mmHg). This unit was ABO compatible
with the patient. The infusion was aborted while corticoste-
roids, epinephrine, diphenhydramine, inhaled levalbuterol,
oxygen via nasal cannula, and lorazepam were administered.
The patient was transferred to the intensive care unit for
observation and a washed graft was administered unevent-
fully. The patient did not require pressors or intubation, had
complete recovery within < 24 hours, and engrafted suc-
cessfully. This patient later had similar reactions to platelets.
Other infrequent reactions included fever (observed), chills
(treated with meperidine), and shoulder or abdominal pain
(treated with slowing of the infusion and/or narcotics).
Seventy-six grafts (55%) administered after dilution were
ABO incompatible with the recipients (26 patients received
grafts inwhich both units hadmajor ABO incompatibility and
50 received grafts in which 1 of the 2 units had major in-
compatibility). However, there was no relationship between
major ABO incompatibility and incidence of grade 1 to 4
infusion reactions. Overall, in 70 of 76 (92%) recipients of
grafts with major ABO incompatibility, there were a total of
97 reactions (including 67 hypertension,13 cardiopulmonary,
and 1 allergic). This compared to 60 reactions in a total of 49
of 60 (82%) recipients of ABO-compatible grafts (including 42
hypertension, 6 cardiopulmonary and 1 allergic). Further-
more, after albumin-dextran reconstitution, the median dose
of RBC/unit was .08 mL/kg (range, .003 to .56). In the 16 pe-
diatric patients with weight 20 kg to 40 kg, the median dose
of RBC/kg was .16 mL/kg (range, .08 to .5). No patient had
macroscopic hematuria or renal impairment.Sustained Donor Engraftment
Five of the 136 patients (3 recipients of myeloablative and
2 of nonmyeloablative conditioning) had graft failure. The
cumulative incidence of sustained donor-derived neutrophil
engraftment by day 45was 95% (95% conﬁdence interval [CI],
88% to 98%) in myeloablative CBT recipients (median recov-
ery, 24 days; range, 13 to 43) and 94% (95% CI, 74% to 99%) innonmyeloablative CBT recipients (median, 10 days; range, 7
to 36) (Figure 1A). The cumulative incidence of day-180
platelet recovery was 86% (95% CI, 77% to 92%) (median, 47
days; range, 29 to 162) and 82% (95% CI, 64% to 92%) (median,
34 days; range, 9 to 59) after myeloablative and non-
myeloablative conditioning, respectively (Figure 1B).DISCUSSION
Preparation of CB units for infusion by thaw of CB fol-
lowed by washing and removal of the supernatant was
originally developed for children and has been used for
larger children and adults by many centers as a matter of
tradition. However, given that autologous products with
higher dimethyl sulfoxide doses are routinely administered
without wash, it stands to reason that infusion of unwashed
CB should be investigated. In CBT, such an approach is even
more desirable, as avoidance of centrifugation results in
considerably less product manipulation and could translate
to lower cell loss. Further additional beneﬁts of a no-wash
approach are less technologist time, lower contamination
rate, and a shorter time between thaw and infusion. Such
advantages can be achieved with albumin-dextran dilution
of the graft. With such an approach, thaw and dilution occurs
in the safety of the laboratory. Additionally, given the graft is
diluted, infusion can be slowed or even temporarily held in
the event of a reaction, without risk of signiﬁcant viability
compromise. This is in contrast to a bedside thaw, in which
infusion of a concentrated product has to be completed
within a short time interval.
Our analysis in 136 patients demonstrates that with
close medical staff supervision, adequate hydration,
appropriate premedication, and prompt management of
infusion reactions, a tolerable infusion reaction proﬁle in
double-unit CBT recipients who underwent transplantation
with RBC-depleted units was achieved. Mild and moderate
reactions were common but easily treated. There were 2
severe reactions: 1 grade 3 angioedema and 1 grade 4
anaphylaxis. From a practical standpoint, it is important to
note that both of these reactions occurred within the ﬁrst
10 minutes of the infusion. This mandates medical staff
be at the bedside during this time, as is the practice
with autologous hematopoietic stem cell products or
platelets, and that emergency medications and oxygen be
available near the bedside for immediate administration, as
needed. Moreover, the patient with severe bronchospasm
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 490e494494subsequently had similar reactions to platelets. Therefore, it
is reasonable to recommend that CBT with dilution not be
performed for any patient with a history of severe reactions
to blood products, or at least not without aggressive pre-
medications and intense monitoring. In addition, as hy-
pertension is the most common infusion reaction, elevated
blood pressure existing before CB infusion should be treated
and controlled before transplantation is initiated, and given
that ﬂuid overload could contribute to hypertension, the
ﬂuid balance should be maintained with intravenous furo-
semide, as needed.
In addition to the tolerable infusion reaction proﬁle, a
high rate of sustained donor neutrophil and platelet
engraftment was observed in this study. It is tempting to
hypothesize that this could be related, at least in part, to
reduced manipulation, resulting in improved product qual-
ity. Although infusion reactions are common, the high rates
of engraftment combined with the fact that most reactions
are easily managed justiﬁes this approach. For these reasons,
we now exclusively use albumin-dextran dilution for thaw
and infusion of RBC-depleted CB units in recipients > 20 kg.
In the decision to adopt an albumin-dextranediluted thaw, it
is important that transplantation centers ensure units are
RBC depleted. Additionally, our results are likely dependent
on adequate dilution, slow infusion, and especially on
prompt infusion reaction management. It is likely that a
lower incidence of reactions could be achieved with inten-
sifying the premedications, such as increasing the dose of
diphenhydramine and/or adding intravenous corticoste-
roids, such as hydrocortisone, and this is now being inves-
tigated at MSKCC since the infusion reactions in this report
have been analyzed.
We do not have any experience with this approach in
patients under 20 kg. Moreover, dilution CBT without
wash is not recommended for transplantation of RBC-
replete units or for patients with prior severe reactions
to blood products. As life-threatening or lethal infusion
reactions have been reported with units that contain high
numbers of RBC, transplantation centers need to be vigi-
lant of the processing methodology at the time of unit
selection. We recommend that if RBC-containing units are
selected, such units are washed and the transplantation
center develop a standard operating procedure for the
centrifugation and reconstitution of these products to
ensure adequate cell recovery. However, the RBC dose in
diluted RBC-depleted products appears to be acceptable.
Despite the lack of wash, the dose of RBC in this study
was well below the dose of 1.5 mL/kg that has been
associated with reactions with autologous bone marrow
infusions [18].
Finally, it is our recommendation that in the setting of
double-unit CBT, the second unit should not be thawed
until the patient is conﬁrmed to be stable during the infusion
of the ﬁrst unit. At our center, because all serious reactions
have occurred during the ﬁrst 10 minutes of infusion, the
medical staff now communicates with the laboratory ap-
proximately 15 minutes into the infusion of the ﬁrst unit
to conﬁrm the appropriateness of commencing the thaw
of the second unit. These procedural interventions permit
infusion of diluted but unwashed products with a high de-
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